Shanxi Zhendong Pharmaceutical Co.,Ltd (SHE:300158)
China · Delayed Price · Currency is CNY 5.75
-0.01 (-0.17%)
Feb 4, 2026, 10:25 AM CST
SHE:300158 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 2,893 | 2,948 | 3,607 | 3,665 | 5,028 | 4,778 |
Other Revenue | 23.6 | 23.6 | 19.37 | 63.98 | 66.1 | 69.71 |
| 2,916 | 2,971 | 3,626 | 3,729 | 5,094 | 4,848 | |
Revenue Growth (YoY) | -6.28% | -18.06% | -2.75% | -26.80% | 5.07% | 10.21% |
Cost of Revenue | 1,740 | 1,812 | 1,830 | 1,894 | 2,058 | 1,825 |
Gross Profit | 1,176 | 1,159 | 1,796 | 1,834 | 3,036 | 3,023 |
Selling, General & Admin | 1,454 | 1,441 | 1,762 | 1,808 | 2,662 | 2,547 |
Research & Development | 318.36 | 349.79 | 189.43 | 178.11 | 218.73 | 136.19 |
Other Operating Expenses | 17.65 | 7.79 | -34.98 | -22.64 | 15.01 | 57.62 |
Operating Expenses | 1,774 | 1,793 | 1,896 | 1,949 | 2,887 | 2,770 |
Operating Income | -597.42 | -634.14 | -99.52 | -114.52 | 148.84 | 253.13 |
Interest Expense | -2.37 | -3.9 | -1.21 | -13.78 | -19.63 | -20.85 |
Interest & Investment Income | 19.26 | 47.64 | 54.67 | 60.7 | 2,959 | 17.02 |
Currency Exchange Gain (Loss) | -0.13 | -0.13 | 0 | 0 | - | 0.01 |
Other Non Operating Income (Expenses) | -5.53 | -2.55 | -11.07 | 28.7 | -20.72 | -1.93 |
EBT Excluding Unusual Items | -586.19 | -593.08 | -57.12 | -38.9 | 3,068 | 247.38 |
Impairment of Goodwill | -24.74 | -24.74 | - | - | -0.49 | - |
Gain (Loss) on Sale of Investments | -141.31 | -139.44 | 1.96 | 11.59 | 0.83 | 0.01 |
Gain (Loss) on Sale of Assets | -0.42 | 10.54 | 0 | -0.86 | -0.49 | -10.73 |
Asset Writedown | -18.86 | -18.77 | -7.62 | -0.94 | -13.15 | -0.02 |
Other Unusual Items | -549.54 | -549.54 | 25.09 | 23.84 | 61.62 | 86.22 |
Pretax Income | -1,321 | -1,315 | -37.69 | -5.28 | 3,116 | 322.86 |
Income Tax Expense | 30.08 | 17.92 | 10.18 | 51.72 | 506.49 | 69.29 |
Earnings From Continuing Operations | -1,351 | -1,333 | -47.87 | -57 | 2,610 | 253.57 |
Minority Interest in Earnings | 2.81 | 4.38 | 3.89 | 5.71 | 7.8 | 8.45 |
Net Income | -1,348 | -1,329 | -43.98 | -51.29 | 2,617 | 262.03 |
Net Income to Common | -1,348 | -1,329 | -43.98 | -51.29 | 2,617 | 262.03 |
Net Income Growth | - | - | - | - | 898.92% | 83.54% |
Shares Outstanding (Basic) | 1,008 | 1,024 | 1,028 | 1,028 | 1,027 | 1,028 |
Shares Outstanding (Diluted) | 1,008 | 1,024 | 1,028 | 1,028 | 1,027 | 1,028 |
Shares Change (YoY) | -5.47% | -0.38% | -0.02% | 0.04% | -0.01% | 0.01% |
EPS (Basic) | -1.34 | -1.30 | -0.04 | -0.05 | 2.55 | 0.26 |
EPS (Diluted) | -1.34 | -1.30 | -0.04 | -0.05 | 2.55 | 0.26 |
EPS Growth | - | - | - | - | 898.98% | 83.59% |
Free Cash Flow | -827.71 | -448.3 | -365.39 | -64.49 | 132.79 | 37.98 |
Free Cash Flow Per Share | -0.82 | -0.44 | -0.36 | -0.06 | 0.13 | 0.04 |
Dividend Per Share | - | - | - | - | 2.800 | 0.070 |
Dividend Growth | - | - | - | - | 3900.00% | 40.00% |
Gross Margin | 40.34% | 39.00% | 49.54% | 49.20% | 59.60% | 62.36% |
Operating Margin | -20.49% | -21.34% | -2.74% | -3.07% | 2.92% | 5.22% |
Profit Margin | -46.23% | -44.72% | -1.21% | -1.38% | 51.39% | 5.41% |
Free Cash Flow Margin | -28.38% | -15.09% | -10.08% | -1.73% | 2.61% | 0.78% |
EBITDA | -499.88 | -526.26 | 22.15 | 11.49 | 273.97 | 419.42 |
EBITDA Margin | -17.14% | -17.71% | 0.61% | 0.31% | 5.38% | 8.65% |
D&A For EBITDA | 97.54 | 107.88 | 121.68 | 126.01 | 125.13 | 166.29 |
EBIT | -597.42 | -634.14 | -99.52 | -114.52 | 148.84 | 253.13 |
EBIT Margin | -20.49% | -21.34% | -2.74% | -3.07% | 2.92% | 5.22% |
Effective Tax Rate | - | - | - | - | 16.25% | 21.46% |
Revenue as Reported | 2,916 | 2,971 | 3,626 | 3,729 | 5,094 | 4,848 |
Advertising Expenses | - | 1.09 | - | - | - | - |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.